Article
Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC.
JCI insight - 8 Feb 2022
Tu Eric, McGlinchey Kelly, Wang Jixin, Martin Philip, Ching Steven Lk, Floc'h Nicolas, Kurasawa James, Starrett Jacqueline H, Lazdun Yelena, Wetzel Leslie, Nuttall Barrett, Ng Felicia Sl, Coffman Karen T, Smith Paul D, Politi Katerina, Cooper Zachary A, Streicher Katie
Abstract excerpt
Treatment with anti-PD-1 and anti-PD-L1 therapies has shown durable clinical benefit in non-small cell lung cancer (NSCLC). However, patients with NSCLC with epidermal growth factor receptor (EGFR) mutations do not respond as well to treatment as patients without an EGFR mutation. We show that EGFR-mutated NSCLC expressed higher levels of CD73 compared with EGFR WT tumors and that CD73 expression was regulated by...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.